drugset / Trial / NCT01588353

Collagenase Option for Reduction of Dupuytren's Contracture in Japan

NCT01588353

Phase 3 Completed 104 enrolled Asahi Kasei Therapeutics Corporation
NaSingle-groupOpen-labelTreatment

Summary

To investigate the efficacy and safety of AK160 in patients with Dupuytren's Contracture. To determine plasma concentration after the first injection of AK160 in patients with Dupuytren's Contracture.

Timeline

Start
2012-05
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Collagenase Clostridium Histolyticum Protein / enzyme biologic 0.58 mg

Indications